Sequenom, Inc. (Nasdaq: SQNM) today announced that it will provide contract genotyping services to Genus plc (LSE: GNS), a world leader in applying quantitative genetics and biotechnology to livestock breeding, for a number of large-scale, high-throughput genotyping projects aimed at accelerating Genus' livestock research and development programs. Financial terms of the contract were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
"We chose Sequenom's services because its proven MassARRAY(R) technology is particularly well-suited for livestock genotyping applications. Additionally, Sequenom has an established performance history and an experienced services team," said Dennis Funk, Ph.D., Group Chief Scientist for Genus.
"Genus, a world leader in the application of genomics to livestock, joins a long list of prominent agriculture-based customers and collaborators that rely on MassARRAY technology," said Harry Stylli, Ph.D., Chief Executive Officer of Sequenom. "Collaborations like this demonstrate the high-value proposition of our MassARRAY platform and recently launched iPLEX(TM) Gold multiplexing assay, which allows for high levels of multiplexing and significantly reduces cost per genotype."
Headquartered in Hampshire, United Kingdom, Genus companies operate in 70 countries on five continents, and have research laboratories in Wisconsin. Genus' technology and products add value throughout the global supply chain of farmers, breeders, processors, distributors, retailers and consumers.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, molecular medicine, agricultural applications, and non-invasive prenatal testing. The Company's proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) are trademarks of SEQUENOM, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the contract genotyping services to be provided by the Company and the high-value proposition of the Company's MassARRAY platform and recently launched iPLEX Gold multiplexing assay, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's technologies, products and services, and other risks detailed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.